Tumor-associated macrophage infiltration in colorectal cancer liver metastases is associated with better outcome

MJ Cavnar, S Turcotte, SC Katz, D Kuk… - Annals of surgical …, 2017 - Springer
MJ Cavnar, S Turcotte, SC Katz, D Kuk, M Gönen, J Shia, PJ Allen, VP Balachandran
Annals of surgical oncology, 2017Springer
Abstract Background Tumor-associated macrophages (TAMs) support growth in most
human cancers, with the notable exception of colorectal adenocarcinoma, in which TAM
infiltration of primary tumors is correlated with a better outcome. The importance of TAMs in
colorectal liver metastases (CLM) is unknown. Methods Using a tissue microarray of CLM
resected at their institution from 1998 to 2000, the authors quantified immune marker
expression by immunohistochemistry (IHC) using Metamorph Image Analysis software …
Background
Tumor-associated macrophages (TAMs) support growth in most human cancers, with the notable exception of colorectal adenocarcinoma, in which TAM infiltration of primary tumors is correlated with a better outcome. The importance of TAMs in colorectal liver metastases (CLM) is unknown.
Methods
Using a tissue microarray of CLM resected at their institution from 1998 to 2000, the authors quantified immune marker expression by immunohistochemistry (IHC) using Metamorph Image Analysis software. Findings showed that CD68, CD3, CD4, CD8, FoxP3, and MHC-I were correlated with overall survival (OS) and disease-free survival (DFS).
Results
Tumor cores from 158 patients were analyzed. The median follow-up period was 117 months for survivors (n = 39). The univariate analysis showed a significant positive association between DFS and CD4+ (p = 0.025) and CD68+ (p = 0.007). The findings showed a significant positive correlation of OS with CD4+ (p = 0.042), whereas the correlation with CD68+ was not significant (p = 0.17). Cutoffs were determined to dichotimize each marker for the highest log-rank statistic. Patients with CD4high had a median OS of 115 months and DFS of 41 months (p = 0.007 compared with 40 and 16 months, respectively, for patients with CD4low (p = 0.022). Patients with CD68high had a median OS of 50 months and a median DFS of 25 months (p = 0.67) compared with 43 and 15 months (p = 0.028). In the multivariate analysis of factors affecting DFS, high CD68 was associated with longer DFS (hazard ratio [HR], 0.63, 95% confidence interval [CI], 0.43–0.94; p = 0.02), independently of clinicopathologic variables and CD4.
Conclusions
High TAM infiltration in resected CLM is associated with better outcome, independently of known clinicopathologic and immune predictors. This suggests that TAM depletion, which is being tested clinically in other cancers, may be detrimental in CLM.
Springer